Actively Recruiting
Pola-ZR2P in Previously Untreated DLBCL
Led by Navy General Hospital, Beijing · Updated on 2025-08-19
80
Participants Needed
1
Research Sites
322 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
CONDITIONS
Official Title
Pola-ZR2P in Previously Untreated DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification
- Patient is 65 18 years of age at the time of signing the informed consent form (ICF)
- Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted
- Patient is willing and able to adhere to the study visit schedule and other protocol requirements
- Patient has not received chemotherapy previously
- Anticipated life expectancy at least 3 months
You will not qualify if you...
- Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment
- Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, PhD
CONTACT
L
Liren Qian, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here